Latest advances and current challenges in the treatment of multiple myeloma. - Wikidata - awgldk - TriplyDB

Latest advances and current challenges in the treatment of multiple myeloma.

Latest advances and current challenges in the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q37986287

about

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma Novel therapeutic strategies for multiple myeloma RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.Differential and limited expression of mutant alleles in multiple myeloma.Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin.In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2.GP130 activation induces myeloma and collaborates with MYC.Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.Identification of aggregation inhibitors of the human antibody light chain repertoire by phage display.Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.Profile of elotuzumab and its potential in the treatment of multiple myeloma Targeting Cdc20 as a novel cancer therapeutic strategy.Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.Ancient hot and cold genes and chemotherapy resistance emergence.The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.Recurrent oral cancer: current and emerging therapeutic approaches.Molecular pathogenesis of multiple myeloma and its premalignant precursor.

P2860

Q24305602-5D52D531-ACCE-44A0-91D9-C44F27C46E97 Q26822754-64ED1C2D-0401-4FD1-8FD7-7CBCEF29EEF3 Q27027729-B05CF399-9FB9-4FF5-B138-925ECF394F6B Q28080823-3F57DCB6-C781-4216-9140-B7259E1DFB0A Q28081590-4C35BC19-B7C2-454B-A787-8D6E5938BF6A Q28260541-8260CDEA-AA3A-43F1-A2A4-53565A6F4775 Q28533426-AEF02BCB-45A4-46A4-B503-C30C63D6E986 Q28534703-B152C05F-AEF5-4CE5-A55B-F997F9AB650C Q28540339-113FB2DC-AB00-441B-A2D4-1E8A42639C5F Q28544663-908BD3A4-D018-4C14-B679-72D8CEA2C5F5 Q33414827-11A628A3-6D87-493C-9553-B5D62BE3D6BF Q33415840-3F909951-96D9-4713-8BCB-330B4209C0D4 Q33617012-8D97F9BC-1291-496E-8BE6-A4DBB5062E4F Q33621587-6CD83B81-675F-403A-BE81-2FE98ABE2C83 Q33738082-4B1628AF-7F91-4CE0-A612-204DD30AE886 Q33747049-63CEE39D-70D1-4CB8-B291-AF05D0D16ECB Q34036138-D6EA9482-919B-4D23-8236-214A907A49F7 Q34038854-DA35111D-7248-40AF-86E1-D6C0ACB01846 Q34075096-B3792871-AC4F-4C7F-9364-48216C56FEAD Q34354073-6E1D1B57-D297-4132-934A-56F05E0D0405 Q34508343-E9D872DF-87B0-463D-B37B-DC83251C9D41 Q34650781-BBC98A36-07B8-4FF7-8250-EB5322598412 Q34656161-BBACA0E5-5F18-4EF4-889E-0A4929B17B33 Q35108549-CB1A4AD1-4C33-4E04-A203-DB8B9D58C64F Q35114405-167038FB-9F5F-476A-8086-2EFF5F0E3BCA Q35145350-709F0AD4-6789-41B5-A814-BC212869D160 Q35182314-BD6F50D6-DECB-4557-A1AC-13AD0B8EACBA Q35211434-E9117DAF-9E09-4A2B-9774-43D389634627 Q35275756-D6B9B549-6AA4-4DA3-8B48-3D63EE3EA853 Q35546925-3FD52351-86EB-4CA7-9025-AFE9656C54AD Q35618595-5498EEB0-18B7-4FA7-A40E-8BC376B28D91 Q35628678-0F64829E-2F7C-409B-A95D-F7155F663EBA Q35688708-448D423E-CF70-4A76-AD7C-3F796EEA6B38 Q35778467-749232E9-6C59-43C7-9933-8410757E3D52 Q35989910-3A90A399-FF5C-4332-8378-9475FAE2F451 Q35996498-0A5262F1-BA05-45FA-BF2E-CAAE0E5511F2 Q36208283-177B835A-2DE0-4FA0-B25B-FB1758FFBAAA Q36229918-489F7279-F569-4781-A698-67B5436B8780 Q36283038-64E6753A-C641-4C56-91BD-F24C2E452782 Q36290238-E0E69F78-99B6-4CD5-8F73-7A845A8AB212

P2860

Latest advances and current challenges in the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q37986287

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Latest advances and current challenges in the treatment of multiple myeloma.

@en

Latest advances and current challenges in the treatment of multiple myeloma.

@nl

type

label

Latest advances and current challenges in the treatment of multiple myeloma.

@en

Latest advances and current challenges in the treatment of multiple myeloma.

@nl

prefLabel

Latest advances and current challenges in the treatment of multiple myeloma.

@en

Latest advances and current challenges in the treatment of multiple myeloma.

@nl

P1433

Q37986287-0183458A-56B0-4F89-A53C-19AFE0E0BCBB

P1476

Q37986287-C2DB8AA6-4496-41F0-9959-28B7C197C8A4

P2093

Q37986287-0DC107E7-E146-462E-AEFE-3E327EB2CDD3

Q37986287-33B80D8A-6908-4ABB-8ABF-D19E039091C2

Q37986287-5ADCE2C0-10EA-408A-A140-359793D7B8C9

Q37986287-80636D5B-E917-4183-AC28-C56128A63B87

P2860

Q37986287-01015A9E-D230-49B0-8A85-7E3CF0F76C86

Q37986287-025F83BB-4A3C-4DCF-840D-FB1B4FDF6EE4

Q37986287-02C4E2A2-7E3E-42B4-8886-9116F1C10291

Q37986287-08C9F1FB-E883-4BE5-8596-09313C14306A

Q37986287-094E5986-B93B-466D-80FF-BCC804D255D3

Q37986287-0D04EC47-486F-4BB6-AEEE-D6A85754426E

Q37986287-10E5324C-2C32-4D0F-A73C-843CB990B5B2

Q37986287-1666DC98-F953-414E-8DE0-857979439F3F

Q37986287-1761B5C8-4FEA-45F8-81ED-0E5314705DBB

Q37986287-1955E9E0-565B-45F8-986A-8182095CD2FB

P304

Q37986287-13540ED3-631C-43F4-9F07-4DC215ABA5F5

P31

Q37986287-4451B64B-FFB6-4D1D-8C13-0C67987A8D26

P356

Q37986287-B92B36B1-6C9B-46EF-A515-9C80F02AB94D

P407

Q37986287-7FAE03EC-83A9-4A97-993E-B24BBD0CE682

P433

Q37986287-CD506E7B-6D61-453A-AB33-C85B5A495A66

P478

Q37986287-3944D953-4FD4-407A-ABF1-AE2CB16AAC51

P50

Q37986287-62543644-10FA-4FC7-9313-80CFDD5F08AF

Q37986287-F7038DC4-6FE7-49B1-B33B-7495463921C4

P577

Q37986287-426B0C19-0B64-4D0F-8801-408685D2DA32

P5875

Q37986287-02F375D8-EB7E-4675-A63D-F382FE22682A

P698

Q37986287-715EBA7B-5778-4840-9875-BFFB761B645C

P356

NRCLINONC.2012.15

P1433

Nature Reviews Clinical Oncology

P1476

Latest advances and current challenges in the treatment of multiple myeloma.

@en

P2093

Anuj Mahindra

http://www.w3.org/2001/XMLSchema#string

Jacob Laubach

http://www.w3.org/2001/XMLSchema#string

Nikhil Munshi

http://www.w3.org/2001/XMLSchema#string

Noopur Raje

http://www.w3.org/2001/XMLSchema#string

P2860

Initial genome sequencing and analysis of multiple myeloma

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Cancer statistics, 2010

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

P304

135-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2012.15

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221846343

http://www.w3.org/2001/XMLSchema#string

P698

22349016

http://www.w3.org/2001/XMLSchema#string